20.500.12556/DiRROS-30053 Remission is maintained after switch from dose-optimised intravenous treatment to subcutaneous treatment with vedolizumab in inflammatory bowel disease inflammatory bowel disease Crohn’s disease ulcerative colitis vedolizumab subcutaneous formulation true false true Angleški jezik Ni določen Neznano 2026-06-12 12:33:54 2026-06-12 12:33:54 2026-06-13 03:52:14 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis z dne 22. 2. 2024; str. 1-12 iss. 2, [article no.] 296 Vol. 60 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.3 1648-9144 10.3390/medicina60020296 186507267 RAZ_Pintar_Spela_2024.pdf RAZ_Pintar_Spela_2024.pdf 1 8CCCE3BD91032E37EF19EF5A75287A4B 390be57c6e342da9fb4c428007241864664af11e623f3007a0fbd1fcbd84ba2b 611e98bc-664a-11f1-aebd-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45328 https://www.mdpi.com/1648-9144/60/2/296 0 3c62769f-664a-11f1-aebd-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45327 Univerzitetni klinični center Ljubljana 0 0 0